1. Kurman RJ, Carcangiu ML, Herrington CS, Young RHE (2014) WHO Classification of Tumors of Female Reproductive Organs. IARC, Lyon
2. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Kurzversion 2.0 – Oktober 2016.
http://www.awmf.org/uploads/tx_szleitlinien/032-035-OLk_Ovarialkarzinom_2016-10.pdf
. Zugegriffen: 30.05.2017
3. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Version 2.0 – Oktober 2016 AWMF-Registernummer: 032/035OL.
http://www.awmf.org/uploads/tx_szleitlinien/032-035-OLl_Ovarialkarzinom_2016-10.pdf
. Zugegriffen: 30.05.2017
4. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH (2014) Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 20:434–444
5. Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M (2010) Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer 20:704–716